In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elixir gets North American rights to Kissei's diabetes drug

Executive Summary

Japanese pharma Kissei licensed Elixir (genetics-based research of age-related, metabolic diseases) exclusive development and marketing rights to its Type II diabetes drug Glufast (mitiglinide calcium hydrate; formerly KAD1229) in the US, Canada, and Latin America. Elixir also gets rights to any Glufast combination products that are developed.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies